Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.

Trial Details

NCT ID
NCT04315233
Phase
PHASE1
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Ribociclib
  • Belinostat
Locations (sample)
  • Salt Lake City, Utah, United States|40.76078,-111.89105
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • For dose escalation cohorts only:
  • \- Pathologically confirmed breast cancer with the following features:
  • Measurable disease by RECIST 1.1;
  • ER and PR ≤ 1% by immunohistochemistry;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →